How Severity Weighting Changes What a Health System Will Pay

Severity weighting is the rule that lets a health system pay more for one unit of health when a disease is severe than when it is mild. It works by multiplying the health a treatment produces before that health is weighed against cost, so a therapy for a devastating condition can clear the same value bar at a higher price. In England, the National Institute for Health and Care Excellence (NICE) does this with a severity modifier that multiplies health gains by 1.2 or 1.7, and it decides which multiplier applies using a measure called QALY shortfall. The result is a higher effective willingness to pay for the sickest patients, set by an explicit formula rather than case-by-case discretion.

The machinery behind a value verdict

Most publicly funded systems judge a new treatment by its cost per quality-adjusted life year (QALY), a unit that combines how much longer a patient lives with how well they live. That number, the incremental cost-effectiveness ratio, is compared against a threshold representing what the system can afford to pay before it starts displacing more health than it buys. NICE has long used a range of roughly 20,000 to 30,000 pounds per QALY, and confirmed in December 2025 that this band will rise to 25,000 to 35,000 pounds per QALY once regulations allow, expected in April 2026, its first threshold change in two decades.

A flat threshold treats every QALY as equal. One healthy year restored to someone with a mild, self-limiting condition counts the same as one healthy year restored to someone dying young. Severity weighting is the deliberate decision to reject that equivalence, on the ethical view that health gains matter more when they go to people who are worse off.

Two ways to measure how badly off a patient is

The modifier needs an objective way to rank severity. NICE uses QALY shortfall: the gap between the lifetime quality-adjusted life expectancy a patient can expect under current care and what a person of the same age and sex would expect in the general population. That gap can be expressed two ways, and the distinction is where much of the policy action lives.

Absolute shortfall is the raw number of quality-adjusted years lost. It captures the total quantity of health foregone, and because young patients have more life ahead to lose, it tends to flag severe conditions that strike early. The peer-reviewed NICE record shows that every decision crossing the highest absolute threshold involved patients under age 20.

Proportional shortfall is the fraction of remaining healthy life lost, the years lost divided by the years otherwise expected. It captures how completely a disease erases what a patient had left, so it can flag severe conditions in older patients who have fewer baseline years but stand to lose most of them. In the NICE data, proportional shortfall peaks around age 60.

NICE applies both and takes whichever yields the higher weight. Absolute shortfall below 12 QALYs, or proportional shortfall below 0.85, earns no uplift; the weight is 1.0. Absolute shortfall of 12 to 18, or proportional shortfall of 0.85 to 0.95, earns a 1.2 multiplier. Absolute shortfall of at least 18, or proportional shortfall of at least 0.95, earns 1.7. Using both measures is a distributional value judgment in itself: it protects both the young patient facing decades of lost life and the older patient losing nearly all of what remained.

How the multiplier becomes a higher price

The weight does not touch the threshold directly. It multiplies the QALYs a treatment delivers, which mathematically lowers the cost per weighted QALY, which is equivalent to raising the price the system will tolerate. Under the current upper threshold of 30,000 pounds, a 1.7 weight means a treatment for the most severe conditions can be accepted at an effective ceiling near 51,000 pounds per unweighted QALY and still be called cost-effective. A 1.2 weight lifts that ceiling to roughly 36,000 pounds. The severity of the disease, quantified as shortfall, becomes a lever on willingness to pay.

Why this replaced the end-of-life rule

From 2009, NICE ran a separate end-of-life provision that gave extra weight, around 1.7 times, to treatments that extended the lives of patients with a short life expectancy, generally under 24 months, by at least three months. That rule was narrow and, in effect, rewarded a particular clinical pattern: terminal illness with a life-extending therapy. Analysis of the NICE record shows it applied almost entirely to older patients, with a mean age near 59.

The 2022 methods manual retired the end-of-life criteria and put the shortfall-based severity modifier in their place. The stated aim was a broader, more consistent basis for extra value, one that could recognize a severe chronic disease in a young person, not only a terminal cancer. The change was also calibrated to be roughly cost-neutral in aggregate. Mean weights before and after the switch were statistically indistinguishable, near 1.12. Severity weighting redistributed which conditions receive priority rather than simply loosening the purse.

What the framework does and does not settle

Severity weighting makes an ethical preference explicit and auditable, which is its central strength. It also embeds choices that remain contested. The Office of Health Economics has noted that NICE's thresholds sit higher than severity cut-offs used elsewhere; the Netherlands treats proportional shortfall of 0.70 as its top tier, and Norway anchors on undiscounted absolute shortfall above 20. Where a country draws its lines, and how steeply it weights, encodes a specific view of fairness that preference research is still working to validate. The mechanism is transparent; the values inside it are a live policy question.

This article is educational and not medical advice. Understanding how these rules work can help readers interpret why a health system funds one treatment and declines another of similar clinical benefit.